Expression vectors encoding epitopes of target-associated...

Details Expression vectors encoding epitopes of target-associated... Expression vectors encoding epitopes of target-associated...

2007-06-19

2007-06-19

Chan, Christina (Department: 1644)

Chemistry: molecular biology and microbiology

Vector, per se

C536S023400, C536S023500, C530S350000, C530S403000, C514S002600, C514S04400A, C424S185100, C424S277100

Reexamination Certificate

active

10777053

ABSTRACT:
The invention disclosed herein is directed to methods of identifying a polypeptide suitable for epitope liberation including, for example, the steps of identifying an epitope of interest; providing a substrate polypeptide sequence including the epitope, wherein the substrate polypeptide permits processing by a proteasome; contacting the substrate polypeptide with a composition including the proteasome, under conditions that support processing of the substrate polypeptide by the proteasome; and assaying for liberation of the epitope. The invention further relates to vectors including a housekeeping epitope expression cassette and also vectors including epitope cluster regions. The housekeeping epitope(s) can be derived from a target-associated antigen. The housekeeping epitope can be liberatable, that is capable of liberation, from a translation product of the cassette by immunoproteasome processing. The invention also relates to a method of activating a T cell comprising contacting a substrate polypeptide with an APC and contacting the APC with a T cell.

REFERENCES:
patent: 4439199 (1984-03-01), Amkraut et al.
patent: 4683199 (1987-07-01), Palladino
patent: 4937190 (1990-06-01), Palmenberg et al.
patent: 5093242 (1992-03-01), Bachmair et al.
patent: 5132213 (1992-07-01), Bachmair et al.
patent: 5168062 (1992-12-01), Stinski
patent: 5258294 (1993-11-01), Boyle et al.
patent: 5385839 (1995-01-01), Stinski
patent: 5405940 (1995-04-01), Boon et al.
patent: 5478556 (1995-12-01), Elliot et al.
patent: 5487974 (1996-01-01), Boon-Falleur et al.
patent: 5496721 (1996-03-01), Bachmair et al.
patent: 5519117 (1996-05-01), Wolfel et al.
patent: 5530096 (1996-06-01), Wolfel et al.
patent: 5554506 (1996-09-01), Van der Bruggen et al.
patent: 5554724 (1996-09-01), Melief et al.
patent: 5558995 (1996-09-01), Van der Bruggen et al.
patent: 5580859 (1996-12-01), Felgner et al.
patent: 5585461 (1996-12-01), Townsend et al.
patent: 5589466 (1996-12-01), Felgner et al.
patent: 5646017 (1997-07-01), Bachmair et al.
patent: 5648226 (1997-07-01), Van den Eynde et al.
patent: 5679647 (1997-10-01), Carson et al.
patent: 5698396 (1997-12-01), Pfreundschuh
patent: 5733548 (1998-03-01), Restifo et al.
patent: 5744316 (1998-04-01), Lethe et al.
patent: 5747269 (1998-05-01), Rammensee et al.
patent: 5844075 (1998-12-01), Kawakami et al.
patent: 5846540 (1998-12-01), Restifo et al.
patent: 5847097 (1998-12-01), Bachmair et al.
patent: 5856187 (1999-01-01), Restifo et al.
patent: 5925565 (1999-07-01), Berlioz et al.
patent: 5962428 (1999-10-01), Carrano et al.
patent: 5989565 (1999-11-01), Storkus et al.
patent: 5993828 (1999-11-01), Morton
patent: 5994523 (1999-11-01), Kawakami et al.
patent: 6004777 (1999-12-01), Tartaglia et al.
patent: 6037135 (2000-03-01), Kubo et al.
patent: 6060273 (2000-05-01), Dirks et al.
patent: 6074817 (2000-06-01), Tartaglia et al.
patent: 6130066 (2000-10-01), Tartaglia et al.
patent: 6287569 (2001-09-01), Kipps et al.
patent: 2003/0186355 (2003-10-01), Ossendorp et al.
patent: 2003/0220239 (2003-11-01), Simard et al.
patent: 2005/0130920 (2005-06-01), Simard et al.
patent: 2147863 (1994-05-01), None
patent: 44 23 392 (1996-01-01), None
patent: 93/03175 (1995-04-01), None
patent: 1118860 (2001-07-01), None
patent: 1181314 (2002-02-01), None
patent: 74899 (1997-08-01), None
patent: WO 92/21033 (1992-11-01), None
patent: WO 96/01429 (1996-01-01), None
patent: WO 96/03144 (1996-02-01), None
patent: WO 96/40209 (1996-12-01), None
patent: WO 97/34613 (1997-09-01), None
patent: WO 97/41440 (1997-11-01), None
patent: WO 98/13489 (1998-04-01), None
patent: WO 98/14464 (1998-04-01), None
patent: WO 98/40501 (1998-09-01), None
patent: WO 99/02183 (1999-01-01), None
patent: WO 99/24596 (1999-05-01), None
patent: WO 99/45954 (1999-09-01), None
patent: WO 99/55730 (1999-11-01), None
patent: WO 00/06723 (2000-02-01), None
patent: WO 00/29008 (2000-05-01), None
patent: WO 00/40261 (2000-07-01), None
patent: WO 00/52157 (2000-09-01), None
patent: WO 00/52451 (2000-09-01), None
patent: WO 00/66727 (2000-11-01), None
patent: WO 00/73438 (2000-12-01), None
patent: WO 01/11040 (2001-02-01), None
patent: WO 01/18035 (2001-03-01), None
patent: WO 01/19408 (2001-03-01), None
patent: WO 01/23577 (2001-04-01), None
patent: WO 01/52614 (2001-07-01), None
patent: WO 01/55393 (2001-08-01), None
patent: WO 01/58478 (2001-08-01), None
patent: WO 01/82963 (2001-11-01), None
patent: WO 01/89281 (2001-11-01), None
patent: WO 01/090197 (2001-11-01), None
patent: WO 02/068654 (2002-09-01), None
patent: WO 00/71158 (2002-11-01), None
patent: WO/03/011331 (2003-03-01), None
patent: WO 2004/018666 (2004-03-01), None
patent: WO 2004/022709 (2004-03-01), None
US 6,008,200, 12/1999, Krieg (withdrawn)
Clark, J et al. Nature Genetics [1994] 7(4):502-508.
Crew, AJ et al. The EMBO Journal [1995] 14(10):2333-2340.
Campbell, A. Monoclonal Antibody Technology [1985] pp. 1-32.
Ayyoub, M et al. J. Immunol. [2002] 168(4):1717-1722.
Lim, FL et al. Oncogene [1998] 17:2013-2018.
Bergmann, et al. “Differential Effects of Flanikng Residues on Presentation of Epitopes from Chimeric Peptides.” J. Virol. 5306-5310 (1994).
Celis, et al. “Identification of Potential CTL Epitopes of Tumor-Associated Antigen Mage-1 for Five Common HLA-A Alleles.” Mol. Immunol. 31(18): 1423-1430 (1994).
Chaux, et al. “Estimation of the Frequencies of Anti-Mage-3 Cytotytic T-Lymphocyte Precursors in blood from Individuals without Cancer.” Int. J. Cancer. 77:538-542 (1998).
Eisenlohr, et al. “Flanking Sequences Influence the Presentation of an Endogenously Synthesized Peptide to Cytotoxic T Lymphocytes.” J. Exp. Med. 175: 481-487 (1992).
Gileadi, et al. “Effect of Epitope Flanking Residues on the Presentation of N-Terminal Cytotoxic T Lymphocyte Epitopes.” Eur. J. Immunol. 29: 2213-2222 (1999).
Gnjatic, et al. “Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: Correlation with antibody responses.” PNAS USA. 100(15): 8862-8867 (2003).
Gnjatic, et al. “Cross-Presentation of HLA Class I Epitopes from Exgenous NY-ESO-1 Polypeptides by Nonprofessional APCs.” J. Immunol. 170: 1191-1196 (2003).
Ochoa-Garay, et al. “The Ability of Peptides to Induce Ctotoxic T Cells In Vitro Does Not Strongly Correlate with their Affinity for the H-2ld Molecule: Implications for Vaccine Design and Immunotherapy.” Molecular Immunology. 34(3): 273-281 (1997).
Perkins, et al. “Immunodominace: Intramolecular Competition Between T Cell Epitopes.” J. Immunol. 146: 2137-2144 (1991).
Shastri, et al. “Presentation of Endogenous Peptide/MHC Class I Complexes is Profoundly Influenced by Specific C-Terminal Flanking Residues.” J. Immunol. 155: 4339-4346 (1995).
Wang, et al., “New NY-ESO Cancer Peptide or MHC Class II Restricted T Cell Epitopes, Useful as Immunogen and Vaccine for Inhibiting Cancer in a Mammal or as Protection From Metastasis.” N—Geneseq Accession No. AAD14184, Nov. 6, 2001, p. 2.
Theobald, et al. “The Sequence Alteration Associated with a Mutational Hotspot in P53 Protects Cells from Lysis by Cytotoxic T Lymphocytes Specific for a Flanking Peptide Epitope.” J. Exp. Med. 188(6): 1017-1028 (1998).
Wang, et al. “Silencing of Immunodominant Epitopes by Contiguous Sequences in Complex Synthetic Peptides.” Cell. Immunol. 143: 284-297 (1992).
Aki et al., “Interferon-(Induces Different Subunit Organizations and Functional Diversity of Proteasomes,”J. Biochem., 115: 257-269 (1994).
Altuvia et al., “A structure-based algorithm to predict potential binding peptides to MHC molecules with hydrophobic binding pockets,”Human Immunology, 58: 1-11 (1997).
An et al. “A Multivalent Minigene Vaccine, Containing B-Cell, Cytoxic T-Lumphocyte, and ThEpitopes from Several Microbes, Induces Appropriate Responses in Vivo and Confers Protection against More than One Pathogen”,J. Virol; 71(3):2292-302 (1997).
Aria et al., “Isolation o

Affiliated with

Also associated with

Rating

Expression vectors encoding epitopes of target-associated... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Expression vectors encoding epitopes of target-associated..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Expression vectors encoding epitopes of target-associated... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3821406